Loading
Botensilimab is an experimental monoclonal antibody from Agenus in phase 2 trials for colorectal cancer, aimed at CTLA-4.
Botensilimab (AGEN1181) is a monoclonal antibody developed by Agenus. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: Botensilimab is an Fc-enhanced anti-CTLA-4 monoclonal antibody designed to prime a broader anti-tumour immune response, typically studied in combination with balstilimab (anti-PD-1). ClinicalTrials.gov describes the intervention as: An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT05608044, plans to enrol 234 participants (actual) with primary completion expected 2027-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Botensilimab is an Fc-enhanced anti-CTLA-4 monoclonal antibody designed to prime a broader anti-tumour immune response, typically studied in combination with balstilimab (anti-PD-1). Connects to CTLA-4.
1.Botensilimab binds CTLA-4.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Botensilimab" OR ABSTRACT:"Botensilimab" OR TITLE:"AGEN1181" OR ABSTRACT:"AGEN1181") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Botensilimab, not a curated reading list.
Shares Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma, The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation, BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases, Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 and the tag pipeline.
Shares Agenus, Colorectal cancer and the tag pipeline.
Shares Agenus and the tag pipeline.
Shares CTLA-4, Colorectal cancer and the tag pipeline.
Shares CTLA-4, Colorectal cancer and the tag pipeline.
Shares CTLA-4 and the tag pipeline.
Shares CTLA-4 and the tag pipeline.
Shares CTLA-4 and the tag pipeline.